ELIXIR and Toxicology: a community in development

Marvin Martens; Rob Stierum; Emma L. Schymanski; Chris T. Evelo; Reza Aalizadeh; Hristo Aladjov; Kasia Arturi; Karine Audouze; Pavel Babica; Karel Berka; Jos Bessems; Ludek Blaha; Evan E. Bolton; Montserrat Cases; Dimitrios Damalas; Kirtan Dave; Marco Dilger; Thomas Exner; Daan P. Geerke; Roland Grafström; Alasdair Gray; John M. Hancock; Henner Hollert; Nina Jeliazkova; Danyel Jennen; Fabien Jourdan; Pascal Kahlem; Jana Klanova; Jos Kleinjans; Todor Kondic; Boï Kone; Iseult Lynch; Uko Maran; Sergio Martinez Cuesta; Hervé Ménager; Steffen Neumann; Penny Nymark; Herbert Oberacher; Noelia Ramirez; Sylvie Remy; Philippe Rocca-Serra; Reza M. Salek; Brett Sallach; Susanna Assunta Sansone; Ferran Sanz; Haralambos Sarimveis; Sirarat Sarntivijai; Tobias Schulze; Jaroslav Slobodnik; Ralf J.M. Weber; Gerard J.P. van Westen; Craig E. Wheelock; Antony J. Williams; Hilda Witters; Barbara Zdrazil; Anže Županič; Egon L. Willighagen

doi:10.12688/f1000research.74502.2

ELIXIR and Toxicology: a community in development

Marvin Martens^*, Rob Stierum, Emma L. Schymanski, Chris T. Evelo, Reza Aalizadeh, Hristo Aladjov, Kasia Arturi, Karine Audouze, Pavel Babica, Karel Berka, Jos Bessems, Ludek Blaha, Evan E. Bolton, Montserrat Cases, Dimitrios Damalas, Kirtan Dave, Marco Dilger, Thomas Exner, Daan P. Geerke, Roland GrafströmAlasdair Gray, John M. Hancock, Henner Hollert, Nina Jeliazkova, Danyel Jennen, Fabien Jourdan, Pascal Kahlem, Jana Klanova, Jos Kleinjans, Todor Kondic, Boï Kone, Iseult Lynch, Uko Maran, Sergio Martinez Cuesta, Hervé Ménager, Steffen Neumann, Penny Nymark, Herbert Oberacher, Noelia Ramirez, Sylvie Remy, Philippe Rocca-Serra, Reza M. Salek, Brett Sallach, Susanna Assunta Sansone, Ferran Sanz, Haralambos Sarimveis, Sirarat Sarntivijai, Tobias Schulze, Jaroslav Slobodnik, Ralf J.M. Weber, Gerard J.P. van Westen, Craig E. Wheelock, Antony J. Williams, Hilda Witters, Barbara Zdrazil, Anže Županič, Egon L. Willighagen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

25 Downloads (Pure)

Abstract

Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For example, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.

Original language	English
Article number	1129
Number of pages	20
Journal	F1000Research
Volume	10
DOIs	https://doi.org/10.12688/f1000research.74502.2
Publication status	Published - 3 Oct 2023

Bibliographical note

Funding Information:
This work received funding from the European Union’s Horizon 2020 research infrastructure programme via the OpenRiskNet project under grant agreement No. 731075. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 681002 (EU-ToxRisk). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 814572. SN acknowledges BMBF funding under grant number 031L0107. This work was supported by OBERON (https://oberon-4eu.com), a project funded by the European Union's Horizon 2020 research and innovation program under the grant agreement No. 825712. This work was supported by the European Union,'s Horizon 2020 research and innovation program HBM4EU, grant agreement No. 733032 (https://www.hbm4eu.eu). Supported by the European Union’s Horizon 2020 programme under the Marie Skłodowska-Curie grant agreement No. 859891. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. This work was supported by the European Union,'s Horizon 2020 research and innovation program HARMLESS, grant agreement No. 953183. This work was supported by the European Union,'s Horizon 2020 research and innovation program Gov4Nano, grant agreement No. 814401. This work was supported by the Swedish Fund for Research Without Animal Experiments under grant number N2020-0005. This work was supported by the European Union,'s Horizon 2020 research and innovation program NTS-EXPOSURE, Grant agreement ID: 896141. This work was supported by the European Union,'s LIFE program LIFE-APEX, Grant agreement ID: LIFE17 ENV/SK/000355. This study was funded by the German Environment Agency within the PHION project (grant number 3718 674150). The Data Readiness Group is supported, in this ELIXIR Community, by the H2020 Precision Toxicology project (H2020-EU 965406). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome ISA-InterMine project (208381/A/17/Z). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome FAIRsharing project (212930/Z/18/Z). This work received funding from the European Union’s Horizon 2020 research and innovation programme RiskGONE Project under grant agreement No. 814425. NR's research is funded by a Miguel Servet contract (CO19/00060) from Instituto de Salud Carlos III, cofinanced by the European Union. UM (Uni. of Tartu) is grateful for support to Ministry of Education and Research, Republic of Estonia through Estonian Research Council (grant number IUT34-14) and to European Union European Regional Development Fund through Foundation Archimedes (grant number TK143, Centre of Excellence in Molecular Cell Engineering). Development and Implementation of a Sustainable Modelling Platform for NanoInformatics. Linking LRI Ambit chemoinformatic system with the IUCLID substance database to support read-across of substance endpoint data and category formation. This work was supported by the French Ministry of Research and National Research Agency as part of the French MetaboHUB, the national metabolomics and fluxomics infrastructure (Grant ANR-INBS-0010). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement GOLIATH No. 825489. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. The views expressed in this manuscript are solely those of the authors and do not represent the policies of the U.S. Environmental Protection Agency. Mention of trade names of commercial products should not be interpreted as an endorsement by the U.S. Environmental Protection Agency.

Publisher Copyright:
Copyright: © 2021 Martens M et al.

Keywords

ELIXIR
FAIR
interoperability
Toxicology

ASJC Scopus subject areas

General Biochemistry,Genetics and Molecular Biology
General Immunology and Microbiology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.12688/f1000research.74502.2Licence: Creative Commons: Attribution (CC BY)

MartensM2023ELIXIRFinal published version, 893 KBLicence: Creative Commons: Attribution (CC BY)

H2020_RIA_RISKGONE
Lynch, I. (Principal Investigator)
European Commission
1/02/19 → 31/08/23
Project: EU
H2020_COLLAB_NANOSOLVEIT_PARTNER
Lynch, I. (Principal Investigator) & Valsami-Jones, E. (Co-Investigator)
European Commission
1/01/19 → 31/08/23
Project: EU
H2020_RIA_OPENRISKNET_PARTNER
Lynch, I. (Co-Investigator) & Gkoutos, G. (Principal Investigator)
European Commission
1/12/16 → 30/11/19
Project: EU

Cite this

Martens, M., Stierum, R., Schymanski, E. L., Evelo, C. T., Aalizadeh, R., Aladjov, H., Arturi, K., Audouze, K., Babica, P., Berka, K., Bessems, J., Blaha, L., Bolton, E. E., Cases, M., Damalas, D., Dave, K., Dilger, M., Exner, T., Geerke, D. P., ... Willighagen, E. L. (2023). ELIXIR and Toxicology: a community in development. F1000Research, 10, Article 1129. https://doi.org/10.12688/f1000research.74502.2

@article{ec672548427f447f872107d3613cbd62,

title = "ELIXIR and Toxicology: a community in development",

abstract = "Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For example, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.",

keywords = "ELIXIR, FAIR, interoperability, Toxicology",

author = "Marvin Martens and Rob Stierum and Schymanski, {Emma L.} and Evelo, {Chris T.} and Reza Aalizadeh and Hristo Aladjov and Kasia Arturi and Karine Audouze and Pavel Babica and Karel Berka and Jos Bessems and Ludek Blaha and Bolton, {Evan E.} and Montserrat Cases and Dimitrios Damalas and Kirtan Dave and Marco Dilger and Thomas Exner and Geerke, {Daan P.} and Roland Grafstr{\"o}m and Alasdair Gray and Hancock, {John M.} and Henner Hollert and Nina Jeliazkova and Danyel Jennen and Fabien Jourdan and Pascal Kahlem and Jana Klanova and Jos Kleinjans and Todor Kondic and Bo{\"i} Kone and Iseult Lynch and Uko Maran and {Martinez Cuesta}, Sergio and Herv{\'e} M{\'e}nager and Steffen Neumann and Penny Nymark and Herbert Oberacher and Noelia Ramirez and Sylvie Remy and Philippe Rocca-Serra and Salek, {Reza M.} and Brett Sallach and Sansone, {Susanna Assunta} and Ferran Sanz and Haralambos Sarimveis and Sirarat Sarntivijai and Tobias Schulze and Jaroslav Slobodnik and Weber, {Ralf J.M.} and {J.P. van Westen}, Gerard and Wheelock, {Craig E.} and Williams, {Antony J.} and Hilda Witters and Barbara Zdrazil and An{\v z}e {\v Z}upani{\v c} and Willighagen, {Egon L.}",

note = "Funding Information: This work received funding from the European Union{\textquoteright}s Horizon 2020 research infrastructure programme via the OpenRiskNet project under grant agreement No. 731075. This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement No. 681002 (EU-ToxRisk). This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement No. 814572. SN acknowledges BMBF funding under grant number 031L0107. This work was supported by OBERON (https://oberon-4eu.com), a project funded by the European Union's Horizon 2020 research and innovation program under the grant agreement No. 825712. This work was supported by the European Union,'s Horizon 2020 research and innovation program HBM4EU, grant agreement No. 733032 (https://www.hbm4eu.eu). Supported by the European Union{\textquoteright}s Horizon 2020 programme under the Marie Sk{\l}odowska-Curie grant agreement No. 859891. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. This work was supported by the European Union,'s Horizon 2020 research and innovation program HARMLESS, grant agreement No. 953183. This work was supported by the European Union,'s Horizon 2020 research and innovation program Gov4Nano, grant agreement No. 814401. This work was supported by the Swedish Fund for Research Without Animal Experiments under grant number N2020-0005. This work was supported by the European Union,'s Horizon 2020 research and innovation program NTS-EXPOSURE, Grant agreement ID: 896141. This work was supported by the European Union,'s LIFE program LIFE-APEX, Grant agreement ID: LIFE17 ENV/SK/000355. This study was funded by the German Environment Agency within the PHION project (grant number 3718 674150). The Data Readiness Group is supported, in this ELIXIR Community, by the H2020 Precision Toxicology project (H2020-EU 965406). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome ISA-InterMine project (208381/A/17/Z). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome FAIRsharing project (212930/Z/18/Z). This work received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme RiskGONE Project under grant agreement No. 814425. NR's research is funded by a Miguel Servet contract (CO19/00060) from Instituto de Salud Carlos III, cofinanced by the European Union. UM (Uni. of Tartu) is grateful for support to Ministry of Education and Research, Republic of Estonia through Estonian Research Council (grant number IUT34-14) and to European Union European Regional Development Fund through Foundation Archimedes (grant number TK143, Centre of Excellence in Molecular Cell Engineering). Development and Implementation of a Sustainable Modelling Platform for NanoInformatics. Linking LRI Ambit chemoinformatic system with the IUCLID substance database to support read-across of substance endpoint data and category formation. This work was supported by the French Ministry of Research and National Research Agency as part of the French MetaboHUB, the national metabolomics and fluxomics infrastructure (Grant ANR-INBS-0010). This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation program under grant agreement GOLIATH No. 825489. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. The views expressed in this manuscript are solely those of the authors and do not represent the policies of the U.S. Environmental Protection Agency. Mention of trade names of commercial products should not be interpreted as an endorsement by the U.S. Environmental Protection Agency. Publisher Copyright: Copyright: {\textcopyright} 2021 Martens M et al.",

year = "2023",

month = oct,

day = "3",

doi = "10.12688/f1000research.74502.2",

language = "English",

volume = "10",

journal = "F1000Research",

issn = "2046-1402",

publisher = "Faculty of 1000 Ltd",

}

Martens, M, Stierum, R, Schymanski, EL, Evelo, CT, Aalizadeh, R, Aladjov, H, Arturi, K, Audouze, K, Babica, P, Berka, K, Bessems, J, Blaha, L, Bolton, EE, Cases, M, Damalas, D, Dave, K, Dilger, M, Exner, T, Geerke, DP, Grafström, R, Gray, A, Hancock, JM, Hollert, H, Jeliazkova, N, Jennen, D, Jourdan, F, Kahlem, P, Klanova, J, Kleinjans, J, Kondic, T, Kone, B, Lynch, I, Maran, U, Martinez Cuesta, S, Ménager, H, Neumann, S, Nymark, P, Oberacher, H, Ramirez, N, Remy, S, Rocca-Serra, P, Salek, RM, Sallach, B, Sansone, SA, Sanz, F, Sarimveis, H, Sarntivijai, S, Schulze, T, Slobodnik, J, Weber, RJM, J.P. van Westen, G, Wheelock, CE, Williams, AJ, Witters, H, Zdrazil, B, Županič, A & Willighagen, EL 2023, 'ELIXIR and Toxicology: a community in development', F1000Research, vol. 10, 1129. https://doi.org/10.12688/f1000research.74502.2

TY - JOUR

T1 - ELIXIR and Toxicology

T2 - a community in development

AU - Martens, Marvin

AU - Stierum, Rob

AU - Schymanski, Emma L.

AU - Evelo, Chris T.

AU - Aalizadeh, Reza

AU - Aladjov, Hristo

AU - Arturi, Kasia

AU - Audouze, Karine

AU - Babica, Pavel

AU - Berka, Karel

AU - Bessems, Jos

AU - Blaha, Ludek

AU - Bolton, Evan E.

AU - Cases, Montserrat

AU - Damalas, Dimitrios

AU - Dave, Kirtan

AU - Dilger, Marco

AU - Exner, Thomas

AU - Geerke, Daan P.

AU - Grafström, Roland

AU - Gray, Alasdair

AU - Hancock, John M.

AU - Hollert, Henner

AU - Jeliazkova, Nina

AU - Jennen, Danyel

AU - Jourdan, Fabien

AU - Kahlem, Pascal

AU - Klanova, Jana

AU - Kleinjans, Jos

AU - Kondic, Todor

AU - Kone, Boï

AU - Lynch, Iseult

AU - Maran, Uko

AU - Martinez Cuesta, Sergio

AU - Ménager, Hervé

AU - Neumann, Steffen

AU - Nymark, Penny

AU - Oberacher, Herbert

AU - Ramirez, Noelia

AU - Remy, Sylvie

AU - Rocca-Serra, Philippe

AU - Salek, Reza M.

AU - Sallach, Brett

AU - Sansone, Susanna Assunta

AU - Sanz, Ferran

AU - Sarimveis, Haralambos

AU - Sarntivijai, Sirarat

AU - Schulze, Tobias

AU - Slobodnik, Jaroslav

AU - Weber, Ralf J.M.

AU - J.P. van Westen, Gerard

AU - Wheelock, Craig E.

AU - Williams, Antony J.

AU - Witters, Hilda

AU - Zdrazil, Barbara

AU - Županič, Anže

AU - Willighagen, Egon L.

N1 - Funding Information: This work received funding from the European Union’s Horizon 2020 research infrastructure programme via the OpenRiskNet project under grant agreement No. 731075. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 681002 (EU-ToxRisk). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 814572. SN acknowledges BMBF funding under grant number 031L0107. This work was supported by OBERON (https://oberon-4eu.com), a project funded by the European Union's Horizon 2020 research and innovation program under the grant agreement No. 825712. This work was supported by the European Union,'s Horizon 2020 research and innovation program HBM4EU, grant agreement No. 733032 (https://www.hbm4eu.eu). Supported by the European Union’s Horizon 2020 programme under the Marie Skłodowska-Curie grant agreement No. 859891. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. This work was supported by the European Union,'s Horizon 2020 research and innovation program HARMLESS, grant agreement No. 953183. This work was supported by the European Union,'s Horizon 2020 research and innovation program Gov4Nano, grant agreement No. 814401. This work was supported by the Swedish Fund for Research Without Animal Experiments under grant number N2020-0005. This work was supported by the European Union,'s Horizon 2020 research and innovation program NTS-EXPOSURE, Grant agreement ID: 896141. This work was supported by the European Union,'s LIFE program LIFE-APEX, Grant agreement ID: LIFE17 ENV/SK/000355. This study was funded by the German Environment Agency within the PHION project (grant number 3718 674150). The Data Readiness Group is supported, in this ELIXIR Community, by the H2020 Precision Toxicology project (H2020-EU 965406). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome ISA-InterMine project (208381/A/17/Z). The Data Readiness Group is supported, in this ELIXIR Community, by the Wellcome FAIRsharing project (212930/Z/18/Z). This work received funding from the European Union’s Horizon 2020 research and innovation programme RiskGONE Project under grant agreement No. 814425. NR's research is funded by a Miguel Servet contract (CO19/00060) from Instituto de Salud Carlos III, cofinanced by the European Union. UM (Uni. of Tartu) is grateful for support to Ministry of Education and Research, Republic of Estonia through Estonian Research Council (grant number IUT34-14) and to European Union European Regional Development Fund through Foundation Archimedes (grant number TK143, Centre of Excellence in Molecular Cell Engineering). Development and Implementation of a Sustainable Modelling Platform for NanoInformatics. Linking LRI Ambit chemoinformatic system with the IUCLID substance database to support read-across of substance endpoint data and category formation. This work was supported by the French Ministry of Research and National Research Agency as part of the French MetaboHUB, the national metabolomics and fluxomics infrastructure (Grant ANR-INBS-0010). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement GOLIATH No. 825489. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. The views expressed in this manuscript are solely those of the authors and do not represent the policies of the U.S. Environmental Protection Agency. Mention of trade names of commercial products should not be interpreted as an endorsement by the U.S. Environmental Protection Agency. Publisher Copyright: Copyright: © 2021 Martens M et al.

PY - 2023/10/3

Y1 - 2023/10/3

N2 - Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For example, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.

AB - Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For example, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.

KW - ELIXIR

KW - FAIR

KW - interoperability

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=85153106420&partnerID=8YFLogxK

U2 - 10.12688/f1000research.74502.2

DO - 10.12688/f1000research.74502.2

M3 - Article

SN - 2046-1402

VL - 10

JO - F1000Research

JF - F1000Research

M1 - 1129

ER -

ELIXIR and Toxicology: a community in development

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Projects

H2020_RIA_RISKGONE

H2020_COLLAB_NANOSOLVEIT_PARTNER

H2020_RIA_OPENRISKNET_PARTNER

Cite this